Nicole Van Hoey’s Post

We know there are a lot of questions that come with a new FDA approved medication! We hope to answer a few that may be top of mind about Rezdiffra™ (resmetirom). 1. What is Rezdiffra? A new drug called Rezdiffra, an oral thyroid hormone receptor beta- selective agonist, shows promising results in treating Nonalcoholic Steatohepatitis (NASH), now known as metabolic dysfunction-associated steatohepatitis (MASH). 2. What's the big deal? The availability of the first NASH drug,  Rezdiffra, marks a significant advancement in the treatment landscape for NASH, offering hope for improved liver health and overall outcomes. 3. Who can take Rezdiffra?  Rezdiffra is for patients with noncirrhotic Nonalcoholic Steatohepatitis (NASH) with moderate to advanced liver fibrosis. 4. Are there side effects? Like all medicines, Rezdiffra can have some side effects. Some people experienced nausea or diarrhea more often than those who took a placebo (a pill with no medicine in it). However, serious side effects were rare, which is reassuring. 5. Who can I call to talk to about Rezdiffra? The team at Arizona Liver Health is well-equipped to answer any questions about Rezdiffra, and to help determine if Rezdiffra is the right choice for your patients. Check out our website www.azliver.com or give us a call for patient referrals. #Rezdiffra #newmedication #arizonaliverhealth Naim Alkhouri Anita Kohli Richard Manch Ann Moore Yessica Sachdeva David Rios, MD Reichard R. Tessa Janovsky Mazen Noureddin, MD, MHSc Julio Gutierrez MD Meena Bansal Raj Vuppalanchi Elliot Tapper Fatty Liver Alliance Madrigal Pharmaceuticals Summit Clinical Research Michelle Jones Nick Engelke Kelly Black Anne Payne Desirae Trotter John Raslavsky

Important- research all potential side effects to determine if the positive benefits outweighs the negative. Diet & lifestyle have to be part of the treatment, as well as prevention. 

CONTINUITY IS KEY: Uncovering the Impact of Stopping SGLT2i and GLP-1 Receptor Agonists on CKD Patients" A recent study published by the American Society of Nephrology highlights critical insights into the use of SGLT2 inhibitors (SGLT2i) and GLP-1 Receptor Agonists among patients with Chronic Kidney Disease (CKD). The study reveals that discontinuation of these anti-diabetes drugs is notably common and significantly associated with adverse outcomes in these patients. Given the potential impact of these findings, it's crucial for healthcare providers and patients alike to understand the implications of SGLT2i and GLP1R Agonist therapy continuity. As someone deeply invested in health equity, these insights align closely with my work and research efforts, emphasizing the need for equitable access to and sustained use of essential medications among diverse and vulnerable patient populations. 📌 Why This Matters: SGLT2 inhibitors & GLP1R agonists are proven to offer renal protection and reduce cardiovascular risks. Ensuring consistent treatment can lead to better health outcomes and quality of life for CKD patients. I encourage healthcare professionals, patients, and fellow researchers to consider these findings in their practices and ongoing studies. Let's work towards a healthcare system that supports access and equitable health treatment solutions. Study Details: https://bit.ly/JASN0477 #diabetesprevention #Healthcare #HealthEquity

UCB announced that the FDA has approved BIMZELX™ (bimekizumab-bkzx) for the treatment of psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) in adults. Bimzelx is the first and only IL-17A and IL-17F inhibitor approved in the U.S. for these conditions.   All three approvals are supported by Phase 3 clinical studies that showed Bimzelx achieved significant improvements vs. placebo at Week 16, with sustained benefits to Week 52.   #Rheumatology #FDAApproval #Bimzelx #bimekizumab #PsoriaticArthritis #PsA #axSpA #nrAxSpA

Very exciting update on ATAI Life Sciences AG's and Beckley Psytech's Phase 1/2a trial of ELE-101 for Major Depressive Disorder (MDD). ELE-101 is a patent-protected, intravenous formulation of psilocin, which is the active moiety in the body when psilocybin is administered orally. As such, I view ELE-101 as a relatively de-risked asset for its stage of development, as it leverages the robust proof-of-concept data that has been established with psilocybin across multiple trials. Especially, it has the potential to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter (!) treatment paradigm of less than 2 hours. So much larger TAM/business upside. #psychedelics #investing #future

Exciting news in the world of healthcare: the U.S. FDA has recently approved Merck Group therapy, Winrevair, for adults dealing with high blood pressure caused by constriction of lung arteries. This approval brings hope to the approximately 40,000 individuals in the U.S. living with pulmonary arterial hypertension (PAH). For more details on this significant development and the impact of Winrevair, check out the full article here: https://lnkd.in/dKbe_HvB Merck's dedication to advancing cardiovascular health shines through with this approval. Analysts project Winrevair to potentially reach peak sales of $5 billion by 2030, underlining its importance in the treatment landscape. Kudos to Merck for their commitment to addressing challenging conditions like PAH. #HealthcareNews #FDAApproval #PulmonaryHypertension #Winrevair #Merck #CardiovascularHealth #Innovation

OTC proton pump inhibitors (PPIs), highlighting their dual role in providing convenient relief for acid-related issues while also posing risks of overuse and potential long-term side effects. This underscores the importance of balancing accessibility with proper usage guidance. As healthcare professionals, it's crucial to promote informed decisions through patient education to maximize benefits and minimize risks. https://lnkd.in/gtg2rf3T

📣 Exciting update on Beckley Psytech’s Phase 1/2a trial of ELE-101 (IV psilocin) for major depression.   ELE-101 is an intravenous formulation of psilocin designed to provide consistent and controllable drug delivery. As the active metabolite of psilocybin, psilocin has the potential to offer a rapid onset, significantly shorter treatment duration and reduced variability between patients, compared to oral formulations of psilocybin. This could enhance convenience and therapeutic outcomes for patients with depression while reducing the resource burden on healthcare systems   Today’s news release shares initial results from the Phase 1 part of the study and announces that the first patients have been dosed in the Phase 2a part.   Full press release here: https://lnkd.in/e4UfBhgg

🤗 🤗 Properties of Retatrutide powder Sequence: YA1QGTFTSDYSIL2LDKK4AQA1AFIEYLLEGGPSSGAPPPS3 Molecular Formula: C223H343F3N46O70 Molecular Weight: 4845.444g/mol PubChem CID: 474492335 CAS Number: 2381089-83-2 Synonyms: LY3437943 Forms avaliable Raw powder Lyophilized powder in vials 💖 💝 Clinical Trials Phase II trial The latest results from the phase II trial (NCT04881760) showed that after 48 weeks, the percentage change in body weight was -8.7%, -17.1%, – 22.8% and -24.2%. Additionally, the study found that 60% of participants lost more than 15% of their body weight. From a safety perspective, the most common side effects are of a gastrointestinal nature. Therefore, the safety profile of retarglutide is the same as that of other incretin-based treatments. 👉 👉 Phase III trial A Phase III trial (TRIUMPH-3; NCT05882045) began in May to evaluate the effects of retarglutide in patients with established cardiovascular disease and those with severe obesity. The trial is expected to end in November 2025. #weightloss #healthbenefits #obesitytreatment #diabetesmanagement #loseweight #clinicaltrials #glp1receptor #healthylifestyle #weightmanagement #GLP1receptor #CagriSema #ARA-290 #Semiglutide #Tirzepatide #Ozempic #Wegovy #Retatrutide #ResearchStandards #Pharmacompanies #PharmaceuticalIndustries #ReferenceStandards #HealthCare  #Type2diabetes #Snap8 #Peptides #Bioregulator #NAD+ #AOD9046 #BPC-157 #injection #injectable #Epithalon #GHK-Cu #Glutathione #Survodutide #Ipamorelin

What do you mean, you've still got stomach pain? Did you REALLY take your medication? - In a number of population groups, 20% (or more) of individuals carry the CYP2C19*17 allele variation. This means that they are classed as rapid or ultrarapid metabolisers and will likely fail to respond to treatment with proton pump inhibitors (PPIs) at usual doses as they will be unable to sustain therapeutic drug plasma concentrations. This can have serious consequences in patients being treated for H. pylori, but is also quite miserable for patients with reflux. CPIC guidelines recommend using an increased starting dose: 50% in rapid metabolisers, 100% in ultrarapid metabolisers. For ultrarapid metabolisers with the *17/*17 genotype, DPWG guidelines go as far as recommending a 3- to 5-fold dose increase, depending on the drug selected: omeprazole, pantoprazole or lansoprazole. (For those with just one *17 allele, no dosage adjustment is required under these guidelines.) Pharmacogenomic testing should be considered in PPI treatment failure. Your patients will thank you. ----- Kia ora. 👋 I'm Claire. I’m a pharmacist on a mission to empower patients with personalised medication based on their unique genetic makeup. I partner with healthcare providers to provide prescribing guidance that is relevant and actionable for personalised medication management. Click my name + visit my website🎯 #precisionmedicine #pharmacogenetics #pharmacogenomics #pharmacist